The growing importance of Israel and Turkey in clinical trials
By Oximio
With clinical trial populations at risk of oversaturation in the core markets, locations such as Israel and Turkey are rapidly increasing in appeal. This white paper will highlight the strengths of the two markets and identify the advantages available to pharma companies operating in these important emerging locations, supported by clinical trial data by GlobalData. Download to learn more.